Add another Item to this comparison Add Item |
|||||
Basic Information | |||||
Generic Name
|
Amphetamine And Dextroamphetamine | Dexmethylphenidate | Methylphenidate | Atomoxetine | Lisdexamfetamine |
Class
|
Cns Stimulants | Cns Stimulants | Cns Stimulants | Cns Stimulants | Cns Stimulants |
Prescription Generic Available
|
Yes | No | Yes | No | No |
Pregnancy cat.
|
C(us) | C(us) | C(us) | B3(au) C(us) | C(us) |
Approved Age
|
3 And Older | 6 And Older | 6 And Older | 6 And Older | 6 And Older |
Legal Status
|
Schedule Ii (us) | Schedule Ii (us) | Schedule Ii (us) | Pharmacist Only (au) Pom (uk) Schedule Ii (us) | |
WADA Category
|
S6 - Stimulants | S6 - Stimulants | |||
Dependence Liability
|
High | High | Moderate | ||
Excretion
|
Urinary | Urinary | Urinary | Renal (>80%) And Fecal ( | Renal: ~2% |
Possible Side Effects
|
Some Loss Of Appetite, Weight Loss, Sleep Problems, Irritability, Tics. | Some Loss Of Appetite, Weight Loss, Dry Mouth, Indigestion, Headaches, Anxiety, Throat Pain, Indigestion, Stomach Cramps | Some Loss Of Appetite, Weight Loss, Sleep Problems, Irritability, Tics. | Sleep Problems, Anxiety, Fatigue, Upset Stomach, Dizziness, Dry Mouth. Rarely, Liver Damage | Some Loss Of Appetite, Weight Loss, Sleep Problems, Irritability, Tics. |
0Comments
|
|||||
Dosage, Usage and Forms | |||||
Routes (of administration)
|
(medical) Oral, Insufflated, Intravenous | Oral | Oral | Oral | Oral |
Dosage
|
5 Mg Q Am–40 Mg Q Am | 6-17: 5 Mg Q Am–30 Mg Q Am; Adults: 10 Mg Q Am-40 Mg Q Am | 20 Mg Q Am–60 Mg Q Am | 30 Mg Q Am–70 Mg Q Am | |
Maximum daily dose
|
40 mg |
40 mg |
60 mg |
70 mg |
|
Duration
|
Long-acting | Long-acting | Intermediate-acting | Long-acting | Long-acting |
Duration - time
|
10-14 H | 8-12 H | 4-8 H | 24 h |
8-12 H |
Chemical Data | |||||
Molecular mass (g/mol)
|
135.21 G/mol | 269.77 G/mol | 269.77 G/mol | 255.36 G/mol 291.81 G/mol (hydrochloride) | 263.378 G/mol |
Half Life
|
10 Hours |
2-4.5 Hours | 5-8 Hours | 5 Hours |
< 1 Hour (prodrug Molecule), 12-13 Hours (d-amphetamine) |
Formula
|
C9h13n | C14h19no2•hcl | C14h19no2•hcl | C17h21no | C15h25n3o |
Bioavailability
|
Nasal 75%; Rectal 95-99%; Intravenous 100% | 30 % |
30 % |
63-94% |
28 % |
Protein binding
|
15 % |
12-15% |
16 % |
40 % |
|
Metabolism
|
Hepatic | Hepatic | Hepatic | Hepatic, Via Cyp2d6 | Gastro-intestinal (initial); Hepatic (extensively Cyp2d6) After Conversion To D-amphetamine |
cancel